Modern Retina | Ophthalmology News, Events & Expert Insights
WEBSeptember 18th 2024. Atsena Therapeutics receives Orphan Drug Designation from FDA for ATSN-201 gene therapy to treat X-linked retinoschisis. By David Hutton. September 17th 2024. ANI Pharmaceuticals completes acquisition of Alimera Sciences. By David Hutton. September 17th 2024. The current state of gene therapy …
Distinction between lamellar holes and macular pseudoholes
WEBMar 12, 2018 · Dr. Thompson defined pseudomacular holes as a clinical diagnosis as seen via slit lamp biomicroscopy versus optical coherence tomography (OCT). “Use pseudomacular holes only to describe the biomicroscopic appearance,” he added. In contrast, a lamellar macular hole is defined by the appearance of the fovea via OCT.
BETTIS-1 Phase 2 trial enrolls and doses first patient with DME
WEBAug 15, 2024 · EC-104 is a novel intravitreal (IVT) corticosteroid implant with intended 6 months durable drug release for the treatment of DME. Eclipse Life Sciences has enrolled and dosed its first patient in the BETTIS-1 Phase 2 clinical trial (NCT06536491) for EC-104 fluocinolone acetonide (FA) extended release. This candidate is a novel intravitreal (IVT ...
ASRS releases public service announcement that shines spotlight …
WEBAug 16, 2024 · The American Society of Retina Specialists (ASRS) has released new national television and radio public service announcements (PSAs) to highlight the role of retina specialists in preventing blindness in millions of Americans who experience retinal detachment, age-related macular degeneration (AMD), …
Vitamin D deficiency may be instrumental in retinal vein occlusion
WEBAug 17, 2024 · Vitamin D supplementation may play a critical role in preventing retinal vein occlusion (RVO), 1 according to the investigators from the Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran. The authors noted the growing body of evidence that suggests that maintaining adequate levels of vitamin D may be beneficial for preventing and ...
Pursuant Health received 510(k) clearance from FDA for kiosk …
WEBJan 16, 2024 · Pursuant Health shared that the company's newest kiosk model, which is now equipped with state-of-the-art retinal imaging technology, received 510 (k) clearance from the U.S. Federal Drug Administration (FDA). The kiosk is the first to offer self-service retinal imaging, empowering individuals to capture their own images.
FDA notifies Ocugen to begin expanded access program for RP …
WEBAug 6, 2024 · The United States Food and Drug Administration (FDA) notified Ocugen, Inc. to begin its expanded access program (EAP) for the treatment of patients, aged 18 and older, with retinitis pigmentosa (RP) with OCU400. This treatment is a modifier gene therapy product candidate currently in the seeing positive results in clinical trials.
SHRM characteristics impact visual acuity in wet AMD - Modern …
WEBAug 14, 2017 · Investigators found that SHRM that was taller, had a layered appearance, increased reflectivity, and larger size were associated with worse visual acuity at the 12- and 24-week follow-up examinations. Dr. Kumar and colleagues have reported previously that larger SHRM is associated with poor visual outcomes and the lesion size does decrease with ...
Lupin's phase 3 trials for ranibizumab biosimilar reaches primary …
WEBAug 6, 2024 · Lupin has successfully completed a global, phase 3 clinical study of LUBT010. This candidate is a ranibizumab biosimilar to Lucentis. The study achieved its primary endpoint, which was equivalence in visual acuity improvement for wet AMD patients, showcasing comparable safety and immunogenicity between …
4DMT shares data from Phase 1/2 PRISM clinical trial, 4FRONT …
WEB3 days ago · 1. 4DMT highlights robust and durable clinical activity for 4D-150 along with design for 4FRONT phase 3 program at 4D-150 wet AMD development Day. 4D Molecular Therapeutics. September 18, 2024. Accessed September 18, 2024. 4D Molecular Therapeutics has announced data based on the longest interim follow-up from Phase 1/2 PRISM clinical trial and ...